COVID19 vaccine in myasthenia gravis patients: safety and possible predictors of disease exacerbation
Neurol Sci
.
2023 Feb;44(2):447-450.
doi: 10.1007/s10072-022-06584-w.
Epub 2022 Dec 25.
Authors
Assunta Trinchillo
1
,
Marcello Esposito
2
,
Francesco Habetswallner
2
,
Francesco Tuccillo
2
,
Bernardo Maria De Martino
2
Affiliations
1
Department of Neurosciences, Reproductive Sciences and Odontostomatology, Federico II" University, Via S. Pansini, 5, 80131, Naples, Italy. assuntatrinchillo94@gmail.com.
2
Clinical Neurophysiology Unit, Cardarelli Hospital, Naples, Italy.
PMID:
36567408
PMCID:
PMC9790762
DOI:
10.1007/s10072-022-06584-w
No abstract available
Publication types
Letter
MeSH terms
COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Disease Progression
Humans
Myasthenia Gravis* / complications
Substances
COVID-19 Vaccines